000 01755 a2200445 4500
005 20250515102752.0
264 0 _c20080805
008 200808s 0 0 eng d
022 _a1619-7070
024 7 _a10.1007/s00259-007-0659-z
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aLam, Marnix G E H
245 0 0 _aCombined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.
_h[electronic resource]
260 _bEuropean journal of nuclear medicine and molecular imaging
_cApr 2008
300 _a756-65 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aBone Density Conservation Agents
_xadverse effects
650 0 4 _aBone Neoplasms
_xdrug therapy
650 0 4 _aCombined Modality Therapy
650 0 4 _aDiphosphonates
_xadverse effects
650 0 4 _aHumans
650 0 4 _aImidazoles
_xadverse effects
650 0 4 _aInjections, Intravenous
650 0 4 _aMale
650 0 4 _aMetabolic Clearance Rate
650 0 4 _aNeoplasm Metastasis
650 0 4 _aOrganometallic Compounds
_xadministration & dosage
650 0 4 _aOrganophosphorus Compounds
_xadministration & dosage
650 0 4 _aProstatic Neoplasms
_xpathology
650 0 4 _aRadioisotopes
_xadministration & dosage
650 0 4 _aSamarium
_xadministration & dosage
650 0 4 _aZoledronic Acid
700 1 _aDahmane, Amel
700 1 _aStevens, Wil H M
700 1 _avan Rijk, Peter P
700 1 _ade Klerk, John M H
700 1 _aZonnenberg, Bernard A
773 0 _tEuropean journal of nuclear medicine and molecular imaging
_gvol. 35
_gno. 4
_gp. 756-65
856 4 0 _uhttps://doi.org/10.1007/s00259-007-0659-z
_zAvailable from publisher's website
999 _c17668901
_d17668901